Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men

Abstract Non-alcoholic steatohepatitis (NASH) is the most rapidly growing liver disease that is nevertheless without approved pharmacological treatment. Despite great effort in developing novel NASH therapeutics, many have failed in clinical trials. This has raised questions on the adequacy of precl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Anita M. van den Hoek, Lars Verschuren, Martien P. M. Caspers, Nicole Worms, Aswin L. Menke, Hans M. G. Princen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/b01d71c202e84e7d903bdef458f54ea0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!